These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 20498641)

  • 21. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
    Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
    Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
    EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
    Chandrasekher G; Sailaja D
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3577-88. PubMed ID: 15452065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
    Alimandi M; Romano A; Curia MC; Muraro R; Fedi P; Aaronson SA; Di Fiore PP; Kraus MH
    Oncogene; 1995 May; 10(9):1813-21. PubMed ID: 7538656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.
    Lu J; Tan M; Huang WC; Li P; Guo H; Tseng LM; Su XH; Yang WT; Treekitkarnmongkol W; Andreeff M; Symmans F; Yu D
    Clin Cancer Res; 2009 Feb; 15(4):1326-34. PubMed ID: 19228734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.
    Knuefermann C; Lu Y; Liu B; Jin W; Liang K; Wu L; Schmidt M; Mills GB; Mendelsohn J; Fan Z
    Oncogene; 2003 May; 22(21):3205-12. PubMed ID: 12761490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):511S-5S. PubMed ID: 12538508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells.
    Söderlund K; Pérez-Tenorio G; Stål O
    Int J Oncol; 2005 Jan; 26(1):25-32. PubMed ID: 15586221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
    Engels K; Knauer SK; Loibl S; Fetz V; Harter P; Schweitzer A; Fisseler-Eckhoff A; Kommoss F; Hanker L; Nekljudova V; Hermanns I; Kleinert H; Mann W; du Bois A; Stauber RH
    Cancer Res; 2008 Jul; 68(13):5159-66. PubMed ID: 18593915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells.
    Aoudjit F; Vuori K
    Oncogene; 2001 Aug; 20(36):4995-5004. PubMed ID: 11526484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quercetin decreases the expression of ErbB2 and ErbB3 proteins in HT-29 human colon cancer cells.
    Kim WK; Bang MH; Kim ES; Kang NE; Jung KC; Cho HJ; Park JH
    J Nutr Biochem; 2005 Mar; 16(3):155-62. PubMed ID: 15741050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
    Yu D; Liu B; Jing T; Sun D; Price JE; Singletary SE; Ibrahim N; Hortobagyi GN; Hung MC
    Oncogene; 1998 Apr; 16(16):2087-94. PubMed ID: 9572489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway.
    Stoica GE; Franke TF; Wellstein A; Morgan E; Czubayko F; List HJ; Reiter R; Martin MB; Stoica A
    Oncogene; 2003 Apr; 22(14):2073-87. PubMed ID: 12687010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
    Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
    Ishizawar RC; Miyake T; Parsons SJ
    Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.